Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice
- PMID: 20406967
- DOI: 10.1158/0008-5472.CAN-09-4354
Tumor-initiated inflammation overrides protective adaptive immunity in an induced melanoma model in mice
Abstract
We studied the effect of the immune system on two differentially aggressive melanomas developing in mice on conditional deletion of the INK4A/ARF tumor suppressor gene, with concomitant expression of oncogene H-Ras(G12V) and a natural cancer-germline tumor antigen (TA). "Slow progressor" melanomas contained no activated T lymphocytes (TL). In contrast, "aggressive" melanomas were infiltrated by activated TLs lacking effector molecules and expressing high levels of PD-1, indicating an exhausted phenotype. Aggressive melanomas were also infiltrated by immature myeloid cells (IMC). Infiltration was associated with local inflammation and systemic Th2/Th17-oriented chronic inflammation that seemed to impair further activation of TLs, as tumor-specific T cells adoptively transferred into mice bearing aggressive melanomas were poorly activated and failed to infiltrate the melanoma. This immunosuppression also led to the incapacity of these mice to reject inoculated TA-positive tumors, in contrast to slow-progressing melanoma-bearing mice, which were responsive. To test the role of adaptive immunity in tumor progression, we induced melanomas in immunodeficient RagKO compound mice. These mice developed aggressive but not slow-progressing melanomas at a higher frequency and with a shorter latency than immunocompetent mice. Immunodeficient mice also developed abnormal inflammation and infiltration of IMCs in a manner similar to immunocompetent mice, indicating that this phenotype was not dependent on adaptive immunity. Therefore, tumor-intrinsic factors distinguishing the two melanoma types control the initiation of inflammation, which was independent of adaptive immunity. The latter delayed development of aggressive melanomas but was overridden by inflammation.
(c)2010 AACR.
Similar articles
-
An inducible mouse model of melanoma expressing a defined tumor antigen.Cancer Res. 2006 Mar 15;66(6):3278-86. doi: 10.1158/0008-5472.CAN-05-3216. Cancer Res. 2006. PMID: 16540681
-
Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.Melanoma Res. 2007 Jun;17(3):169-76. doi: 10.1097/CMR.0b013e3281844531. Melanoma Res. 2007. PMID: 17505262
-
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background.Cancer Res. 2005 May 15;65(10):4005-11. doi: 10.1158/0008-5472.CAN-04-2970. Cancer Res. 2005. PMID: 15899789
-
Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity.Int J Exp Pathol. 2006 Jun;87(3):163-76. doi: 10.1111/j.1365-2613.2006.00478.x. Int J Exp Pathol. 2006. PMID: 16709225 Free PMC article. Review.
-
Pathways to melanoma development: lessons from the mouse.J Invest Dermatol. 2002 Oct;119(4):783-92. doi: 10.1046/j.1523-1747.2002.00217.x. J Invest Dermatol. 2002. PMID: 12406321 Review.
Cited by
-
IFNγ producing CD8+ T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas.Oncoimmunology. 2015 Mar 6;4(2):e974959. doi: 10.4161/2162402X.2014.974959. eCollection 2015 Feb. Oncoimmunology. 2015. PMID: 25949872 Free PMC article.
-
Control of CD8 T cell proliferation and terminal differentiation by active STAT5 and CDKN2A/CDKN2B.Immunology. 2015 Aug;145(4):543-57. doi: 10.1111/imm.12471. Epub 2015 Jun 15. Immunology. 2015. PMID: 25882552 Free PMC article.
-
Redox Properties, Bioactivity and Health Effects of Indicaxanthin, a Bioavailable Phytochemical from Opuntia ficus indica, L.: A Critical Review of Accumulated Evidence and Perspectives.Antioxidants (Basel). 2022 Nov 29;11(12):2364. doi: 10.3390/antiox11122364. Antioxidants (Basel). 2022. PMID: 36552572 Free PMC article. Review.
-
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2. Nat Commun. 2017. PMID: 28928446 Free PMC article.
-
Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8+ T-cell therapy.Oncoimmunology. 2014 Dec 15;3(10):e958951. doi: 10.4161/21624011.2014.958951. eCollection 2014 Oct. Oncoimmunology. 2014. PMID: 25941582 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases